Scarica l'app Stockscreener
27.77
3.61%
-1.04
Dopo l'orario di chiusura:
27.23
-0.54
-1.94%
Precedente Chiudi:
$28.81
Aprire:
$29.19
Volume 24 ore:
1.02M
Relative Volume:
1.00
Capitalizzazione di mercato:
$1.66B
Reddito:
-
Utile/perdita netta:
$-103.69M
Rapporto P/E:
-14.95
EPS:
-1.8579
Flusso di cassa netto:
$-70.46M
1 W Prestazione:
-5.67%
1M Prestazione:
+3.93%
6M Prestazione:
+39.13%
1 anno Prestazione:
+36.87%
Intervallo 1D:
$27.45
$30.06
Intervallo di 1 settimana:
$27.45
$30.98
Portata 52W:
$13.30
$30.98
Enliven Therapeutics Inc Stock (ELVN) Company Profile
Nome
Enliven Therapeutics Inc
Settore
Industria
Telefono
720-647-8519
Indirizzo
6200 LOOKOUT ROAD, BOULDER
Compare ELVN vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ELVN
Enliven Therapeutics Inc
|
27.77 | 1.66B | 0 | -103.69M | -70.46M | -1.8579 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.34 | 119.23B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
745.77 | 78.84B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
700.45 | 43.35B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
313.41 | 41.57B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
284.05 | 31.51B | 5.36B | 287.73M | 924.18M | 2.5229 |
Enliven Therapeutics Inc Stock (ELVN) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-06-16 | Iniziato | Goldman | Buy |
| 2024-12-13 | Iniziato | BTIG Research | Buy |
| 2024-09-09 | Iniziato | H.C. Wainwright | Buy |
| 2024-06-11 | Iniziato | Robert W. Baird | Outperform |
| 2024-04-09 | Iniziato | Mizuho | Buy |
| 2023-03-29 | Iniziato | Jefferies | Buy |
Mostra tutto
Enliven Therapeutics Inc Borsa (ELVN) Ultime notizie
Energy Moves: Should I trade or invest in Enliven Therapeutics IncEarnings Recap Report & Fast Exit and Entry Strategy Plans - baoquankhu1.vn
Enliven Therapeutics (NASDAQ:ELVN) CFO Benjamin Hohl Sells 10,000 Shares of Stock - MarketBeat
Enliven Therapeutics (NASDAQ:ELVN) Reaches New 1-Year HighShould You Buy? - MarketBeat
Enliven Therapeutics (ELVN) Form 144: Director sales total 45,000 shares - Stock Titan
Smart Money: Is Enliven Therapeutics Inc a speculative investment2025 Technical Overview & Consistent Income Trade Recommendations - baoquankhu1.vn
TD Asset Management Inc Sells 39,388 Shares of Enliven Therapeutics, Inc. $ELVN - MarketBeat
(ELVN) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
VIX Spike: Will Enliven Therapeutics Inc benefit from rising consumer demandQuarterly Portfolio Report & Accurate Buy Signal Notifications - baoquankhu1.vn
Enliven Therapeutics stock hits 52-week high at 30.29 USD - Investing.com Nigeria
Enliven Therapeutics (ELVN) Projected to Post Earnings on Thursday - MarketBeat
Enliven Therapeutics stock hits 52-week high at 30.29 USD By Investing.com - Investing.com Canada
Enliven Therapeutics has cash runway into 2029 - BizWest
Enliven Therapeutics (NASDAQ:ELVN) Hits New 1-Year HighTime to Buy? - MarketBeat
ELVN Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Enliven Therapeutics Q4 Loss Widens - marketscreener.com
Enliven Therapeutics (stock code: ELVN) recently released its financial report for the fourth quarter and full year of fiscal 2025, while also updating the market on the company's latest business developments. - Bitget
Enliven Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025 - marketscreener.com
Enliven Therapeutics (NASDAQ: ELVN) advances ELVN-001 toward pivotal CML trial - Stock Titan
Enliven Therapeutics (NASDAQ: ELVN) touts ELVN-001 data and $462.6M cash runway - Stock Titan
Enliven Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides a Business Update - PR Newswire
ELVN: ELVN-001 shows strong efficacy in CML, with pivotal data and phase 3 launch expected in 2024 - TradingView
Enliven Therapeutics Reports Third Quarter Financial Results and Provides a Business Update - mx.advfn.com
Head-To-Head Review: ProPhase Labs (NASDAQ:PRPH) & Enliven Therapeutics (NASDAQ:ELVN) - Defense World
ELVN SEC FilingsEnliven Therapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Enliven Therapeutics (NASDAQ:ELVN) Stock Rating Lowered by Wall Street Zen - MarketBeat
ELVN Should I Buy - Intellectia AI
Enliven Therapeutics, Inc. (ELVN) Stock Analysis: Exploring a 37.94% Upside Potential in Biotech - DirectorsTalk Interviews
Enliven Therapeutics to Present at the TD Cowen 46th Annual Health Care Conference - Finviz
Insider Trends: Can Enliven Therapeutics Inc disrupt its industryJuly 2025 Recap & AI Powered Market Entry Strategies - baoquankhu1.vn
(ELVN) Risk Channels and Responsive Allocation - Stock Traders Daily
Enliven Therapeutics, Inc. (NASDAQ:ELVN) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Enliven Therapeutics, Inc. (ELVN) Stock Analysis: A Biotech Gem with 58% Upside and Strong Buy Ratings - DirectorsTalk Interviews
Enliven Therapeutics (NASDAQ:ELVN) Director Sells $32,201.40 in Stock - MarketBeat
Heyman, Enliven Therapeutics director, sells $32k in stock By Investing.com - Investing.com Canada
Plan-based 1,230-share sale by Enliven (ELVN) director disclosed - Stock Titan
Investment Report: Is SAIL forming a double bottomInsider Buying & Weekly Momentum Stock Picks - baoquankhu1.vn
Market Catalysts: Is Enliven Therapeutics Inc a speculative investment2025 Institutional Moves & Verified Entry Point Detection - baoquankhu1.vn
Gains Report: Is First Internet Bancorp showing insider buyingJuly 2025 Action & High Conviction Investment Ideas - baoquankhu1.vn
Enliven Therapeutics (NASDAQ: ELVN) seller files 75,000-share resale with Jefferies - Stock Titan
Stock Market Recap: How sensitive is Enliven Therapeutics Inc to inflationJuly 2025 Rallies & Safe Capital Investment Plans - baoquankhu1.vn
Enliven Therapeutics, Inc. (NASDAQ:ELVN) Short Interest Down 14.1% in January - MarketBeat
Can Enliven Therapeutics Inc disrupt its industryQuarterly Portfolio Summary & Breakout Confirmation Alerts - baoquankhu1.vn
45,000 Enliven Therapeutics (NASDAQ: ELVN) shares set for sale - Stock Titan
Will Enliven Therapeutics Inc. benefit from rising consumer demandJuly 2025 EndofMonth & Free Expert Verified Stock Movement Alerts - mfd.ru
What drives Enliven Therapeutics Inc.’s stock priceJuly 2025 Breakouts & Growth Focused Stock Reports - mfd.ru
Is Enliven Therapeutics Inc. stock attractive for income investorsProduct Launch & Daily Stock Trend Watchlist - mfd.ru
(ELVN) Movement as an Input in Quant Signal Sets - Stock Traders Daily
History Review: Can Enliven Therapeutics Inc disrupt its industryWeekly Market Outlook & Smart Allocation Stock Tips - baoquankhu1.vn
Candriam S.C.A. Raises Stock Position in Enliven Therapeutics, Inc. $ELVN - MarketBeat
Enliven Therapeutics (NASDAQ:ELVN) Insider Sells $145,200.00 in Stock - MarketBeat
Lyssikatos, Enliven Therapeutics CSO, sells $145k in shares By Investing.com - Investing.com UK
Enliven Therapeutics Inc Azioni (ELVN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.48%
1.21%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):